Skip to content

Clinical trials

Leukemia, Myeloid, Acute trials in China with unknown status

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia, Myeloid, Acute Status: Unknown status Country / region: China Clear all

143 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20102
20111
20122
20133
20146
20152
20168
20179
201817
201913
202013
202126
202223
202315
20243

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status143

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
The First Affiliated Hospital of Soochow University19
Nanfang Hospital, Southern Medical University9
PersonGen BioTherapeutics (Suzhou) Co., Ltd.7
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.4
Chinese PLA General Hospital4
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences4
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.3
Ge Zheng3
Huihan Wang3
Peking University People's Hospital3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia, Myeloid, Acute143
Myelodysplastic Syndromes17
Recurrence15
Leukemia11
Leukemia, Myeloid7
Hematologic Neoplasms4
Precursor Cell Lymphoblastic Leukemia-Lymphoma4
Lymphoma3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive2
Myeloproliferative Disorders2

Trials

Showing 1 to 25 of 143. Each trial links to its page on Pharma Observatory.

43 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.